The Oncology Brothers Discuss Data Presented at ASCO 2023 on Sacituzumab Govitecan for HR+/HER2‒ Metastatic Breast Cancer
The Oncology Brothers—Rahul Gosain, MD, of the University of Rochester, and Rohit Gosain, MD, of the UPMC Hillman Cancer Center—were live at ASCO 2023 to discuss findings from the TROPiCS-02 study with Aditya Bardia, MD, of Massachusetts General Hospital at Harvard Medical School. Dr. Bardia discussed the Trop-2-directed antibody-drug conjugate sacituzumab govitecan, which is FDA-approved for patients with metastatic triple-negative breast cancer in the first-line and later setting, as well as patients with metastatic hormone receptor-positive (HR+) breast cancer who have received at least 2 prior lines of systemic therapy. ...
Advertisement
Advertisement
Advertisement

DocWire Content Partners

Expert Interviews

Network Websites